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2. Abstract 
Background: Previous studies of hyperbaric oxygen (HBO) treatment on chemically 
induced and murine breast cancer models have shown promising results. This study 
was performed to elucidate the effects of HBO on a human breast cancer model, in an 
effort to make the results more clinically relevant. Our objective was to develop a 
human breast cancer model (MDA-MB-231) in NOD/SCID mice. This model was to 
be exposed to early or late hyperbaric oxygen therapy to evaluate effects concerning 
tumor growth, angiogenesis and proliferation. Finally, we wanted to elucidate if the 
effect of chemotherapy could be enhanced by HBO.  
Methods: Immunodeficient NOD/SCID mice were injected with the MDA-MB-231 
cells to form tumors. Mice were divided in six groups: controls (early and late), HBO 
(early and late), chemotherapy (5FU) and HBO/5FU. Controls were exposed to 
normal ambient pressure air throughout the experiment, while HBO treatment was 
performed with pure oxygen 4 times (each 90 min) at 2.5 bar. 5FU was given 
immediately prior to HBO treatment in the combined group. Tumor growth was 
measured by a caliper. Immunostaining was used to discover differences in blood 
vessels (CD-31) and proliferating cells (KI-67).  
Results: The tumor model developed with 100 % take. Tumor growth was 
significantly inhibited in the early treated HBO group compared to controls, but not 
after late treatment. No differences were found in angiogenesis or proliferation 
between HBO and controls neither in the early nor the late group. Tumor size was not 
significantly different after the combined HBO/5FU treatment than after HBO alone. 
Conclusion:  We can conclude that MDA-MB-231 tumor establishment was 
successful. HBO inhibits tumor growth significantly if given early, but not when 
administered late. This inhibitory effect could not be explained by differences in 
blood vessels or proliferating cell densities. HBO did not potentiate the effect of 5FU 
in this tumor model. Further studies are needed. 
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4. Introduction 
4.1 Cancer  
4.1.1 Cancer incidences 
Yearly, there are an estimated 12.7 million new cancer cases on a worldwide basis. 
Breast cancer is one of the most common forms of cancer, with approximately 1.38 
million new cases each year (approximately 11% of all cancer cases) (1). A total of 
7.6 million people annually die of cancer (around 13% of all deaths). 458 000 deaths 
per year are caused by breast cancer, constituting 6% of cancer deaths (2). The reason 
death rates are lower in breast cancer than in general, are that the majority of cancer 
cases occur in developed countries (1) were good treatment options coincidentally are 
also more easily accessible to the general population. However, cancer, along with 
cardiac disease, represents the leading causes of mortality in developing and 
developed regions. Thus, finding new efficient treatment options is of great 
importance. The numbers presented are from 2008. 
4.1.2 Cancer characteristics 
Cancer is an abnormal cell growth. Cancer may progress into malignancy if 
oncogenes are activated or tumor suppressor genes are inhibited (3). Cancer cells 
proliferate at a higher rate and are eliminated at a lower rate than regular somatic 
cells. This disruption of homeostasis causes invasion and the following destruction of 
healthy tissues. The danger of cancer lies in the fact that a tumor will deplete the 
nutrient supply of nearby tissues, that gradually will starve to death (3). The illnesses 
known as cancer are genetically quite diverse, and the mutation rate is high. But 
cancer most often displays certain universal characteristics according to a review by 
Hanahan et Weinberg, 2011 (4) (Fig 1):  
 Sustaining proliferative signaling: Growth factors affect the size of cells and 
changes normal cell cycle progression. In doing so, the growth factors are 
disrupting the homeostasis of cell number that exists in non-cancerous tissues. 
There are several ways by which cancer cells can maintain proliferative 
signaling: Cancer cells are provided these growth signals by themselves (5-8) 
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or by stromal cells (9, 10). Cancer cells can also increase the amount of 
receptors for growth factors, or bypass the need for growth factors by 
activating cellular mechanisms downstream of the receptors (4).  
 
 Evading growth suppressors: Cancer cells must avoid the systems that reduce 
cell proliferation. Among these are the tumor suppressor genes. The tumor 
suppressors gets signals from outside and within the cell and this information 
decides whether cells should be allowed to proliferated or enter senescence or 
be eliminated by apoptosis. In malignancy, enough of the genes coding for 
tumor suppressor genes have been rendered dysfunctional. Normal cells are 
regulated by contact inhibition, a system that most cancer cells have escaped.  
 
 Inducing angiogenesis: Tumor cells needs provision of nutrients and oxygen 
and removal of carbon monoxide and waste products like all other cells. In an 
adult, angiogenesis, formation of new blood vessels from existing vasculature, 
is almost non-existent. While in a tumor an “angiogenic switch” is almost 
constantly turned on to promote the tumor growth (11). Vascular endothelial 
growth factor (VEGF) is a a prominent example of a gene that promotes 
angiogenesis. Expression is increased by both hypoxia and oncogene signaling 
(12-14). The angiogenesis derived from such signaling does, however, 
produce abnormal and malfunctioning blood vessels (15, 16). The 
angiogenesis is induced early in cancer development (11, 16). There also exist 
angiogenesis inhibitors, several different have been discovered, that 
counteracts the angiogenetic program of tumors (17-20). 
 
 Enabling replicative immortality: Normal cells have limited replicative 
potential. After a given number of mitosis, cells will either enter senescence or 
die. Cancer cells proliferate without limitations. Based on several studies, the 
telomeres that protect DNA during replication are associated with this 
mechanism (21, 22). In normal cells the telomeres are shortened by each 
replication, and this eventually exposes chromosomes to destruction that make 
further replications impossible. The enzyme telomerase, that continuously 
restores the telomeres, is highly prevalent in cancer cells. Though this 
mechanism is not always this straight forward. 
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 Resisting cell death: Apoptosis is controlled cell death that does not cause 
inflammations of the surrounding tissues. Apoptosis prevents normal cells 
from progressing into malignancy (23-25). Increased oncogene signalling and 
DNA damage acquired as a result of hyperproliferation, normally induces 
apoptosis in cells. However, cancer cells having reached a higher level of 
malignancy, and not responding predictably to therapy, can attenuate the 
process of apoptosis (23, 25). Commonly cancer cells escape apoptosis if the 
tumor suppressor qualities of TP53 are lost. Cancer cells may also 
downregulate pro-apoptotic factors, prevent the extrinsic death pathway or 
increase expression of antiapapoptotic genes or of survival signals. Autophagy 
is the process of cells disintegrating themselves by means of their lysosomes. 
Autophagy, another mechanism of eliminating abnormal cells, can be induced 
by cellular stress like nutrient deficiency (26, 27). In addition to being harmful 
for cancer cells, autophagy can also be of benefit because it makes cellular 
components readily available for surrounding surviving cancer cells. 
Autophagy represents another obstacle for tumor cells to overcome in order to 
progress towards malignancy. (28) Necrosis is externally caused cell death 
that leaves cell debris. When cells die by necrosis, in contrast to apoptosis, 
proinflammatory signals are released to the surroundings. This attracts 
inflammatory cells from the immune system (29-31). These cells normally 
functions by evaluating the tissue damage and removing waste products. 
However, in relation to cancer cells, immune inflammatory cells can be 
beneficial if they are able to induce angiogenesis, cancer cell proliferation and 
invasiveness. These cells can also emit factors that promote cell proliferation 
of surrounding cells (30). Thus, although a proportion of cancer cells will be 
eliminated, the tumor as a whole might benefit from a certain degree of 
necrosis. 
 
 Activating invasion and metastasis: When tumors form metastasis and invade 
other tissues, the cancer malignancy increases notably. Cells change shape, 
and their attachment to adjacent cells and the extracellular matrix are altered, 
a process associated, amongst others, with the loss of an important cell-to-cell 
adhesion molecule called E-cadherin in cancer cells. Hence, a functional E-
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cadherin suppresses invasion and metastasis significantly (32, 33). In addition, 
other genes expressing similar qualities along with genes promoting cytostasis 
are generally downregulated. Invasion and metastasis occurs as a cascade of 
events (34, 35). First the cancer cells invade the immediate surroundings. 
Then the cells intravasate through the basal membrane and into the blood and 
lymph stream before they exit the vessels in a new organ and enters its 
parenchyma. Micrometastases are formed, and finally, as proposed by several 
studies, macroscopic metastasis emerge in the step called “colonization”. 
Responsible for this process, except for the final step of colonization, is a 
program termed “epithelial-mesenchymal transition” (EMT) that alters cells, 
enabling them to go through this process (36-40). Communicative signaling, 
previously shown between cancer and stromal cells, reinforces the invasion 
and metastasis (41-44). 
 
In the last years there have been emerging new hallmarks due to improved 
insight into the complexity of tumor biology (4): 
 Deregulating cellular energetics: In order for cancer cells to perform all 
actions leading to increased malignancy, they require not only a certain 
signaling, but also an altered energy metabolism to support the high level of 
proliferation and growth. Normally in aerobic cells, glucose is metabolized to 
pyruvate by glycolysis. Then pyruvate is metabolized to carbon dioxide and 
water in the mitocondria in the oxidative phosphorylation, using a lot of 
oxygen in the process. This last step optimizes the amount of ATP produced 
in metabolism. For anaerobic tissues, in contrast, glycolysis alone is preferred. 
However, studies have shown that cancer cells do not follow these regulations 
(45-47). Cancer cells are able to switch to only glycolysis even in an oxygen-
rich environment, the “aerobic glycolysis”. The amount of ATP gained here is 
relatively low. Therefore the cancer cells compensates, for instance by 
upregulating glucose transporters, especially GLUT1, resulting in higher 
glucose uptake (48-50). A connection has been discovered between glycolysis 
and activation of oncogenes as well as mutations of tumor suppressor genes. 
(e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53) (48-50). In the 
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situation of hypoxia, glucose transporters are upregulated in addition to 
enzymes involved in the glycolytic pathway (48, 50, 51). Like the oncoprotein 
Ras, hypoxia can elevate HIF1 and HIF2 transcription factor levels, aiding 
glycolysis (51-53).  When trying to understand why cancer cells prefer 
glycolysis, there has been made a hypothesis stating that the increased 
glycolysis releases glycolytic compounds to mechanisms that generates cell 
materials (54, 55). This in turn facilitates new cell generation. Additionally, 
tumors may have two distinct metabolisms. The first type already mentioned 
produces lactate as a byproduct, and the other cell type uses lactate as fuel 
mediated by parts of the citric cycle (56-58). This mechanism can also be 
found in muscle tissue (56-58). The cancer metabolism is programmed by 
many of the same genes that induce the other hallmarks.  
 
 Avoiding immune destruction: The immune system presents a notable barrier 
to cancer progression, demonstrated by various clinical studies. Studies using 
animals lacking different immune system components, revealed a heightened 
risk of cancer. Based on this, it was concluded that both the innate and 
acquired immune system protect against cancer (59, 60). In transplantation 
studies cancer cells from immunodeficient mice are not able to form new 
tumors in mice with a functional immune system (59-61). But in the opposite 
situation, the cells could metastasize. The assumption derived from this is that 
caner cells prevailing in a normal animal model, were weakly immunogenic, 
meaning they create a small response in the immune system. Having this 
characteristic enables cancer cells to successfully form tumors. However, 
tumors with highly immunogenic cells can also survive by disabling certain 
immune system processes (62, 63). In addition, there is the recruitment of 
immunosuppressive inflammatory cells that benefit cancer progression (64, 
65).  
 
There are also enabling characteristics that allow cancer cells to acquire the above-
mentioned hallmarks (4):  
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 Genome instability and mutation: Mutated genomes will sometimes gain 
competitive advantages over the unaltered cells. They will proceed to 
eventually dominate in number compared to other genome types. These 
mutations results in certain cases to a more cancerous cell. The changes are not 
always mutations. Instead epigenetic mechanisms might be responsible (66-68). 
Although mutations occur regularly, the genome maintenance systems correct 
most of the errors in the DNA, keeping the mutation rate fairly low. However, 
the genomes of cancerous cells often mutates at a higher rate to achieve all the 
genes required for successful cancer development (69, 70). This occurs as a 
result of diminished resistance against the mutagenic agents, of a 
malfunctioning in the genomic  maintenance machinery or through 
inadequacies of the DNA surveillance systems normally operating, especially 
by the tumor suppressor TP53 (71-73). Interestingly, since a cancerous cell 
without telomeres will gain DNA damage, telomerase seems to function both as 
a tumor promoter as well as a tumor suppressor (74). 
 
 Tumor-promoting inflammation: It has long been known that certain tumors 
contain cells from the immune system, much like in tissues with inflammation 
(75). Now, through analysis with more sophisticated techniques, it appears that 
virtually every tumor contains such cells (76). Traditionally this gathering of 
immune cells was assumed to occur to eliminate the cancer tissue. However, for 
a while now, research has been indicating the opposite. The inflammatory 
response increases cancer malignancy, as many studies have shown (30, 44, 77, 
78). Cells of the immune system are able to release mutagenic chemicals and 
reactive oxygen species that affect surrounding cancer cells (30).  
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Figur 1: Hallmarks of cancer, modified from Hanahan and Weinberg, 2011 (4) 
4.2 Hypoxia 
Hypoxia is a common feature in solid tumors. Tumors are dependent upon removal of 
carbon dioxide and waste products and of being supplied by oxygen and nutrients to 
grow. Initially during tumor growth, diffusion from the surroundings suffices to 
oxygenate the tumor. However, when the tumor reaches a certain size (about 2 mm), 
it needs to form new blood vessels to get enough oxygen for the cells to survive, a 
process called angiogenesis. The blood vessels often grow in an inadequate manner 
and are usually leaky (4). Due to improper blood vessel formation there are perfusion 
limitations in the tumor. Furthermore, the diffusion distances greatly limits oxygen 
saturation of the tumor. This leaves tumor cells in a hypoxic state.  Thus, there are 
often large hypoxic regions in the center of tumors of moderate (4-10 µm) or larger 
sizes (79, 80). The oxygen concentration in tumors ranges from the normoxic 
periphery, through the hypoxic middle regions to the inner anoxic centre (81, 82). The 
low oxygen concentration centrally leads on to necrosis (82). The tumor regions 
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depleted of oxygen, but not to the degree of necrosis, enters a static phase without 
mitosis. 
Despite the fact that the hypoxia of solid tumors can have negative consequences, it 
has been shown that hypoxia promotes tumor growth, angiogenesis and metastasis 
and reduces the efficacy of cancer therapies in several different fashions. Thus, cells 
that thrive in the hypoxic environment will harbour an aggressive phenotype leaving 
patients with poor prognosis (83-88) 
Since hypoxia leads to more cancerous cells, hypoxia might therefore be an important 
target in cancer therapy. We therefore predict that targeting hypoxia might reduce or 
even remove some of the cancer characteristics discussed in section 4.1.2, resulting in 
a less malignant tumor. There are several ways of opposing the hypoxia, hyperbaric 
oxygen was chosen in this study. 
4.3 Hyperbaric oxygen (HBO) therapy 
Hyperbaric oxygen (HBO) therapy is to intermittently expose a subject to 100% 
oxygen at a higher than normal ambient pressure. Under normobar and normoxic 
conditions haemoglobin is approximately 97% saturated with oxygen, which equals 
19.5 vol% The blood plasma, however, only has 0.32 vol% dissolved oxygen. HBO 
does not significantly alter the O2 binding to haemoglobin, but increase the amount of 
O2 dissolved in the blood. At a pressure of 3 atmosphere (atm) combined with 100% 
oxygen, plasma oxygen levels are raised to 6 vol%, a 95% increase. HBO treatment 
also markedly increases the diffusion range for oxygen in tissues (89). After HBO 
treatment, the oxygen partial pressure (pO2) will remain elevated for up to an hour 
(90). Partial pressure equals the pressure exerted by each of the constituents of a 
mixture of gasses. 
There are several laws explaining why hyperbaric oxygen therapy is a successful 
method for creating a hyperoxic tumor environment: 
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Henry’s law:   C = kPgass 
Where C is the concentration of a gass in solution, k is the constant for the solution 
and Pgass is the partial pressure of the gass above the liquid. This law explains the 
balance between partial pressure of a gass in a gass mixture and the concentration of 
the same gas in a liquid when the liquid and gass mixture are in direct contact.  
The relevance of Henry’s law in this study is to understand how much of the oxygen 
in the lungs of the mice that will dissolve in blood plasma during HBO treatment.    
Boyle’s law: PV = K 
Where P er absolute pressure, V is volume og K is a constant. In a gas with a fixed 
temperature and amount, volume and pressure will be inversely proportional. When 
pressure is elevated, volume is reduced and vice versa. This law is important when 
considering how to compress and decompress an oxygen chamber with living animals 
inside.  
Fick’s principle: VdCi = F(Ca - Cv) dt  
Where Ci, Ca and Cv are gass concentrations in tissue, arterial and venous blood 
respectively. F is perfusion, t is time and V is volume. This equation is used to find 
the amount of substance uptake, in this study a gas, for an organ or a tissue in a given 
time period. Uptake equals the gass concentration in arterial blood minus its 
concentration in venous blood multiplied by perfusion. Tissues will continue to 
receive the dissolved gass until equilibrium is reached between blood plasma and 
tissue. Fick’s principle explains the rate of tissue oxygenation during HBO treatment 
if all oxygen is provided by the blood vessels. The inadequate blood vessel structure 
of tumors will of course influence the tissue oxygen saturation as well.  
Hyperbaric oxygen is used in non-cancerous tissues for treating several diseases like 
decompression sickness, carbon monoxide poisoning, wounds and necrotic ulcers, as 
defined by the Undersea and Hyperbaric Medical Society (UHMS). HBO is also 
known to induce angiogenesis in areas lacking proper perfusion. 
  
10 
10 
4.3.1 HBO and breast cancer  
HBO in combination with cancer therapy, has for many years been studied with the 
main objective to evaluate if HBO had a tumor promoting effect. Two reviews have 
concluded that HBO does not enhance tumor growth (91, 92).  
Feldmeier et al. (92)  compared animal studies on HBO and all types of cancer 
from1966 to 2001 (93-108). There was no primary or metastatic tumor growth in 15 
of 17 studies. Two of 17 studies showed growth, one model of lung cancer (105) and 
a chemically induced cancer model (103), although these two may not necessarily be 
reliable because of the experimental conditions. Tumor inhibitory results were gained 
in 4 studies (93, 94, 101, 108), and 2 studies had mixed results (103, 104). These 
diverging results probably reflect the many different variables, like the number of 
treatments and treatment pressure. Furthermore, Some tumors were induced by tumor 
transplants, others by cell injections or chemical induction,and many different tumor 
types were studied (in many different animals as well).  
An unpublished review by Stuhr and Moen (2012) evaluated HBO studies from 2004-
2012 and suggested that tumor types should be an important factor  to look at when 
evaluating if HBO treatment works, since we know that no common treatment has 
been shown to be efficient in all types of cancer. They divided the research after 
cancer type and found that breast and head and neck cancers showed tumor inhibition 
when treated with HBO while cervical and bladder and prostate cancers were non-
responders. 
So several studies by our laboratory (109-115) and others (114) have shown that 
HBO inhibits different types of breast cancer in vivo and in vitro. They all used 
clinically relevant HBO protocols.  
An anti-angiogenetic effect was often correlated with the tumor reduction of HBO 
(111, 112, 115, 116). Reactive oxygen species (ROS) were measured to be neutral 
indicating that differences in ROS concentration do probably not cause the tumor 
inhibition (111). HBO as an adjuvant for chemotherapy had a positive effect both in 
vivo and in vitro in several studies (111, 113, 117), however no effect was found in 
one study (115). The effect of HBO on metastases is still unsure. Studies of DMBA 
induced breast tumors exposed to HBO, induced  increased cell death, reduced 
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proliferation and changed histology (110, 112). Most interesting was probably the 
shift in an entire gene program from epithelial to mesenchymal transition (EMT) to 
mesenchymal to epithelial transition (MET), indicating oxygen to be an important key 
in this switch to less malignant tumor. 
 When treating DMBA induced rat tumors with HBO and 5FU both separately and in 
combination, a significant inhibition of tumor growth was measured between controls 
and HBO (for both alone or combined) treated tumors. In addition the combined 
treatment inhibited tumor growth significantly more than HBO alone (113). 
Furthermore, the inhibitory effect was still found 12 days post treatment. 
Previous studies have discovered the same, although these particular studies used 
higher pressure or more exposures (94, 101, 104). The effect of HBO is, by all 
evidences, caused by the elevated oxygen pressure and not by the high pressure (94). 
The main HBO effect on the DMBA induced tumors is summarized in Fig. 1. 
Figure 2:  A summary of the HBO effects previously shown on DMBA 
(chemically) induced mammary tumors (118) 
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A similar inhibitory tumor growth response was found in a 4T1 murine mammary 
tumor model (109, 115), although not as pronounced as in the DMBA model. 
Thus, HBO has shown positive effects against chemically induced and murine breast 
cancer models in previous studies at our laboratory. On this background the next step 
was to use a human breast cancer cell line to be more clinically relevant. It would be 
of interest to see if hyperbaric oxygen treatment could be used as adjuvant therapy in 
the future.  
4.4 Aims 
This study had the following aims:  
1) To develop a human breast tumor (MDA-MB-231) in NOD/SCID mice after 
injecting human breast cancer cells into the groin area  
2) To investigate if HBO (early or late treatment) have an effect on angiogenesis, 
proliferation and growth in the present mammary tumor model  
3) To investigate if HBO potentiate the tumor inhibitory effect of chemotherapy in 
the same mammary tumor model 
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5. Methods and materials 
5.1 Mice 
A total of 44 female NOD/SCID (non-obese diabetic/severe combined 
immunodeficiency) mice (Taconic farms Inc, Denmark), weighing between 20 and 25 
g were used. NOD/SCID mice have a reduced ability to produce T- and B-
lymphocytes because of chromosomal abnormalities. They have less resistance 
against infections, and transplantations are more likely to be accepted by their bodies.  
(119) The NOD mice are used as model animals for type 1 diabetes and other 
autoimmune diseases (120) 
The mice were kept in individually ventilated, pathogen-free cages (Makrolon IV, 
Techniplast Gazzada S.a.r.l., Buggugiate, Italia) at the animal facility at the 
Department of Biomedicine, Bergen, Norway. They had access to food (RMI pellets 
from Special Diets Service, Essex, UK) and water ad libitum, with a room 
temperature of 21 º C and air humidity of 40-60 %. The light/dark cycle was 12/12 
hours. 
 
All the experiments were approved by the Norwegian Committee for Animal 
Research (the Norwegian State Commission for Laboratory Animals and 
experimental procedures).  
5.2 Anaesthesia  
During cell injections and tumor size measurements, the mice were shortly 
anesthetized with Isofluran (Isobal®vet, Schering-Plough Animal Health) and N2O 
gas. The anesthetic was added at a rate of 2-5 l/min. The mouse was first placed in a 
plexiglas anesthetic chamber flushed with O2 (1.0 l/min) combined with compressed 
air (1.0 l/min). During the experiments the mice got anesthesia form a nozzle to the 
nose/mouth area. A heating pad kept the body temperature at 37 º C ± 0.5 º C. All 
mice were sacrificed by CO2. 
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5.3 The cell-line 
A human breast cancer cell line, MDA-MB-231, was used. This breast cancer cell 
line was obtained from American type Culture Collection, Rockville, MD, USA and 
was originally isolated from a 51 year old Caucasian female in 1973 by pleural 
effusions. MDA-MB-231 is a well-established cell line that is efficient in forming 
colonies. The cells have epithelial-like (spindle shaped) morphology. 
5.4 Culturing of cells 
The MDA-MB-231 cells were cultured in F12K medium (Bio-Whittaker, Verviers, 
Belgium) supplemented with 100 ml/L of fetal calf serum, 100 U/L of penicillin and 
100 mg/L of streptomycin (Sigma-Aldrich, Steinheim, Germany). The cells were 
amplified as a monolayer in plastic tissue culture flasks 75 cm
2
 (NUNC, Roskilde, 
Denmark) in a humidified incubator set at 37 º C with 5 % CO2 and 95 % air, and 
were seeded until approximately 80 % confluence. All cell culture work was 
performed in a laminar flow bench with a HEPA filter (Thermo Scientific, USA) 
under sterile conditions. 
5.5 Establishing tumors 
We performed pilot studies to evaluate the amount of cells needed to develop tumors. 
In order to identify the number of cells/ml solution, the cells were trypsinized into a 
single cell suspension and counted using a cell nucleocounter.  
 
200 µl of the single cell suspension were mixed with 200 µl of both buffer A and B 
(Bergman-Nucleocounter-chemometech, Allerød, Denmark) as described by the 
manufacturer.  
 
The lysis Reagent A disrupts the plasma membranes of the cells, allowing the 
fluorescent dye propidium iodide (PI) to stain the nuclei. The Reagent A has a pH of 
about 1.25 and also contributes to disaggregate cell clusters. The stabilizing Reagent 
B was added after Reagent A in order to raise the pH value, because the PI is able to 
stain the DNA in the cells’ nuclei more efficiently in an alkaline environment. 
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The solution was then centrifuged (LABINCO L46, Breda, The Netherlands) directly 
before being loaded into the nucleocassette (Bergman-Nucleocounter-chemometech, 
Allerød, Denmark). The nucleocassette is a disposable cassette filled with PI. The 
cassette automatically loads 50 µl of the cell solution. The PI stains the nuclei of the 
cell, making it possible for the cell nucleocounter to count the number of cells per ml. 
The total amount of cells/ml had to be multiplied by three due to the dilution caused 
by the added buffers.  
 
The rest of the cell suspension was centrifuged (Heraeus instruments, Megafuge 1,0 
R, Hanau, Germany) at 900 rpm for 4 min. The F12 medium was then removed and 
the PBS (Sigma-Aldrich-Company, Steinheim, Germany) was added to the cell pellet 
at an amount calculated as follows: 
 
PBS (added): 
total amount of cells * 0,15 ml 
5 mill cells 
 
The mice were then injected with 5 million cells in 0.15 ml MDA-231 cell solution in 
the fat pad on each side of their mammary crest in the groin area. By day 8, 100% of 
the mice had developed tumors ranging in sizes from 5-8 mm
3
. 
 
The mice were divided into six groups (Table 1): Controls (both early and late), HBO 
(both early and late), 5FU (the chemotherapeutic drug Fluorouracil 50 mg/ml. iv. 
Hospira Nordic AB, Stockholm, Sweden) and combined HBO and 5FU. The control 
and HBO group each contained 17 mice over all, while the 5FU and combined HBO 
and 5FU group each contained 5 mice. To distinguish between the mice within each 
group, their tails were marked using a permanent marker.  
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Table 1: The different experimental groups: 
Experimental 
groups   
Number 
of mice 
Gas 
Ambient 
pressure 
(bar) 
Days from 
injection to 
treatment 
Days of 
treatment 
Exposure 
time 
(min) 
Number 
of 
exposures 
Controls 
Early  10 Air 1 7 11 - - 
Late 7 Air 1 24 11 - - 
HBO 
Early 10 100% O2 2.5 7 11 90 4 
Late 7 100% O2 2.5 24 11 90 4 
5FU 5 Air 1 7 11 - - 
HBO/5FU 5 100% O2 2.5 7 11 90 4 
   
5.6 HBO treatment 
 
The Hyperbaric Animal Research Chamber OXYCOM 250 ARC (HYPCOMOY, 
Tampere, Finland) was used (Fig 2). This is a cylindrical pressure chamber in which 
the inner diameter is 25 cm, the inner length is 55 cm and the volume is 27 liters. The 
chamber is equipped with a gas in- and out-let and a manometer monitoring pressure 
in the chamber. To prevent fire in a pure O2 environment, no litter was allowed into 
the chamber.  
 
First the chamber was flushed with pure O2 (medical quality) until reaching 100 % O2 
(~15 minutes). Then the pressure was slowly increased from 1 to 2.5 bar (equivalent 
to 15 msw) over approximately 10 minutes. Over a period of 90 minutes, the 
atmosphere inside the chamber was kept at this level. To ensure an atmosphere 
containing >97 % O2 at all times during the 2.5 bar period, the chamber was flushed 
with pure O2 for 5 minutes every 10-15 minutes. After the treatment the chamber was 
slowly decompressed to 1 bar (~ 10-15 minutes). The mice underwent this treatment 
on days 1, 4, 7 and 10. Day 1 being either 7 days (early treatment) or 24 days (late 
treatment) after the injection of tumor cells. 
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Figure 2: The hyperbaric oxygen chamber 
 
5.7 Chemotherapy  
The chemotherapeutic drug Fluorouracil (5FU) (Hospira Nordic AB, Stockholm, 
Sweden) was given as 50 mg/ml. iv. in all the mice in the 5FU group and the 
5FU/HBO group on identical days as the HBO treatments (Day 1, 4, 7 and 10). 
The preparing of 5FU injections was performed under an extractor hood. A dose of 
1.5 mg/kg in 0.2 ml saline was injected intraperitoneally between the tumors, 
immediately prior to the HBO treatment in the combined group. 
5.8 Measurements of tumor growth 
The tumors were measured with a caliper on days 1, 4, 7 and 11 or day 1 and 11. The 
location of the tumor did only allow measurements in two dimensions. The best 
estimate of tumor volume given these restrictions was a calculation based on a 
cylindrically shaped tumor according to this equation: 
(π/6) * a2 * b 
 
 where a is the shortest and b is the longest transversal diameter.  
 
On day 1 if the tumors had an abnormal shape, this was drawn on a schematic mouse 
to ensure that the tumor was measured equally along the same axis on the remaining 
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days. Additionally, body weights of mice were measured on the first and last day to 
get an indication of any treatment influence on their health.  
5.9 Immunohistochemistry 
On the last day of measurements, the tumors were quickly dissected out, snap frozen 
in liquid nitrogen and stored at –80ºC until further use. The frozen tumor tissue was 
embedded in Tissue Tek (Sakura Fintek Europe, Zoeterwounde, the Netherlands) and 
cut into 10-20 µm slices with a cryostat microtome (Leica CM 3050 S-Cryostat, 
Nussloch, Germany).  
5.9.1 CD-31 
To stain for tumor blood vessels, CD-31 was used. CD-31 is also called platelet 
endothelial cell adhesion molecule (PECAM-1). It’s a protein that is present on the 
surface of platelets, monocytes, neutrophils and certain varieties of T-cells and targets 
blood vessels. The frozen slides of tumor (20 µm) were immunostained with rat anti-
mouse CD-31 (AbD serotec, Morphosys UK Ltd, Oxford, UK) as primary antibody 
This is a monoclonal antibody, which means that the antibody was produced by cells 
that were clones of each other. Biotinylated rabbit-anti-rat (Vectastatin ABC kit, 
peroxidase Rat IgG PK 4004, Bioteam AS, Trondheim, Norway) was used as 
secondary antibody. Prior to applying the antibodies, rabbit serum was used as a 
blocking agent to avoid nonspecific binding of the secondary antibody. Further, H2O2 
in methanol was used to quench endogenous peroxidases that the Diaminobenzidine 
tetrahydrochloride (3.3 DAB, Sigma-Aldrich, Germany) would otherwise bind to. An 
avidin biotin peroxidase complex was used to bind to the biotinylated secondary 
antibody. To visualize the blood vessels, the chromogen DAB was used.  DAB 
functions as an electron donor, and when oxidized it gets a dark brown color and 
becomes insoluble. Richardssons stain was used to counterstain the rest of the tumor 
tissue. The cross-section of CD-31 positive structures was quantified per mm
2
 using a 
counter grid with 100 x magnification. The entire tumor was measured for cross-
sections. The blood vessel diameter was also measured. Within each tumor 100 
adjacent blood vessels were measured and grouped in 2 µm range clusters. Both 
measurements were performed on a Nikon Eclipse E600 microscope (Nikon 
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Corporation, Tokyo, Japan), using a Nikon Digital Camera DXM 1200F (Nikon 
Corporation, Tokyo, Japan) on pictures of 100 x magnification. The Computer-
software program NIS-Elements AR 3.2 64-bit (Laboratory Imaging Ltd, Prague, 
Czech Republic) was used. 
5.9.2 KI-67 
To be able to quantify proliferating cells, and hence how aggressive the tumor is, we 
used KI-67. The KI-67 protein is an antigen associated with cell proliferation because 
it is detectable in all active phases of the cell cycle, but absent in resting phase. By 
staining for KI-67, it’s possible to determine how many of the tumor cells that were in 
a state of mitosis. It’s also possible to find out where in the tumor most proliferation 
occurs. The 10 µm thin tumor tissue slides were fixed with acetone. Then the primary 
antibody was monoclonal mouse anti-human KI-67 Antigen (Dako Denmark A/S, 
Glostrup, Denmark). One slide was immersed in Mouse IgG1 (Dako Denmark A/S, 
Glostrup, Denmark) to serve as a negative control. The secondary antibody was 
labeled polymer-HRP anti-mouse (Dako Denmark A/S, Glostrup, Denmark). DAB 
(Dako Denmark A/S, Glostrup, Denmark) was used as a chromogen, with 
Richardson’s stain as counterstaining. For each tumor, 4 cross-sections were 
quantified with a counter grid by counting proliferating and non-proliferating cells 
separately. The Nikon Eclipse E600 microscope (Nikon Corporation, Tokyo, Japan) 
and a Nikon Digital Camera DXM 1200F (Nikon Corporation, Tokyo, Japan) were 
used to take pictures of x100 magnification. The Computer-software program NIS-
Elements AR 3.2 64-bit (Laboratory Imaging Ltd, Prague, Czech Republic) was used.  
5.10 Haematoxylin-Eosin staining 
Two frozen section from each group was stained with Haematoxylin-Eosin (HE) to be 
able to visualize any changes in histology between the treatment groups. This was 
performed, but needs to be evaluated by a pathologist. 
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6. Results 
6.1 Establishing tumors 
Pilot studies showed that a total of five million cells were found to be efficient in 
forming tumors when injected into groin area of the mice. Thus, five million MDA-
MB-231 mammary tumor cells were injected subcutaneously in the groin area in all 
our experiments. They formed tumors in the female NOD/SCID mice with a 100 % 
take within 7 days.  
6.2 Body weight 
Throughout the experimental period, the mice maintained stable body weights 
regardless of treatment, indicating no negative treatment effects. 
6.3 Tumor growth 
6.3.1 Early HBO treatment - 7 days post cell injection  
A total of 60 MDA-MB-231 mammary tumors, divided between the four different 
groups, were measured as described under section 5.8 either day 1, 4, 7 and 11 or 
only day 1 and 11. The average tumor size day 1 for all groups was between 100 and 
150 mm
3
, and the control tumors increased by approximately 100% within the 11 day 
experimental period.  
In the early HBO, 5FU and combined treatment group, tumor growth was 
significantly reduced compared to the controls (Fig 1). However, subjected to the 
same treatment, the tumors showed a wide range of responses, indicating the large 
heterogeneity within the tumors. 
HBO induced a significantly greater inhibition of tumor growth compared to 5FU 
after 11 days. Furthermore, after 11 days, the combined treatment reduced tumor 
growth significantly compared to 5FU alone (Fig 3). There was, however, no 
significant difference between tumor size in the HBO and combined treatment group. 
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Thus, HBO did not potentiate the tumor growth reduction by 5FU in this tumor 
model. 
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Figure 3: MDA-MB-231 human mammary tumor growth (% of initial volume) in 
controls (n=20), hyperbaric oxygen (HBO) (n=20), 5-Fluorouracil (5FU) (n=10) and 
combined HBO and 5FU (n=10) treated tumors over a period of 11 days. This early 
treatment was initiated 7 days post cell injection. Treatments were given day 1, 4, 7 
and 10. Mean ± SEM. *p<0.01 **p<0.0001 compared to controls or 5FU. 
6.3.2 Late HBO treatment - 24 days post cell injection  
To compare an early treatment effect of HBO (Fig 4A) with a late treatment effect 
(Fig 4B), an additional 28 MDA-MB-231 mammary tumors, separated in early and 
late control and HBO groups, were measured. 
Tumor size was significantly reduced in the early HBO treated tumors compared to 
controls during the 11 day period (Fig 4A), while exposing the mice to late HBO did 
not induce a significant reduction in tumor growth other than at the 4 day mark. (Fig 
4B) Thus, early HBO treatment induced a statistically significant tumor inhibitory 
effect, while late HBO treatment did not. 
** 
** 
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Figure 4: MDA-MB-231 human mammary tumor growth (% of initial volume) over 
a period of 11 days. A. Early treatment was initiated 7 days post cell injection. B. 
Late treatment was initiated 24 days post cell injection. Treatments were given days 
1, 4, 7 and 10. Mean ± SEM. *p<0.01, ** p<0.0001 compared to controls. 
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n = 20 n = 10 n = 20 n = 10 
n = 14 n = 14 n = 14 n = 14 
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6.4 Tumor blood vessels 
Since angiogenesis is known to greatly influences tumor growth, blood vessels were 
stained using rat anti-mouse CD31 as primary antibody as described under section 
5.9.1.  
The average tumor blood vessel density, was approximately 13 vessels/mm
2
 in all the 
treatment groups (Table 2). Thus, there was no statistically significant difference 
between the groups. 
The average tumor blood vessel diameter was approximately 7 µm in controls and 
HBO regardless of early (Fig 5A) or late (Fig 5B) treatment. Thus, there was no 
significant difference between the groups (Table 1). In these MDA-MB-231 tumors 
there was a heterogeneous blood vessel diameter distribution within each tumor, as 
can be seen Fig 5.  
Based on this, the tumor growth inhibition in the early HBO treated tumors is 
probably not attributed to blood vessel density or size. HBO does not appear to affect 
angiogenesis in this study.  
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Table 2:  Immunhistochemical analysis 
Tumor blood vessel density and diameter (CD31) and proliferation (KI67) in MDA-
MB-231 human mammary tumors from controls and hyperbaric oxygen (HBO) 
treated tumors. n = 5 for all groups. Mean ± SEM. 
  
Early treatment 
7 days post cell 
injection 
Late treatment 
24 days post cell 
injection 
Controls HBO Controls HBO 
Pressure pO2 1 bar 2.5 bar 1 bar 2.5 bar 
% O2 20 100 20 100 
Blood vessels density 
(number/mm
2
)  
13.5 ± 1.59 12.4 ± 1.75 13.5 ± 0.79 13.4 ± 0.65 
Blood vessel diameter 
(µm) 
7.3 ± 1.65 7.2 ± 1.83 7.4 ± 1.35 7.6 ± 1.48 
Proliferation  
(% of Ki67 positive 
cells) 
0.31 ± 0.03 
 
0.28 ± 0.01 
 
0.36 ± 0.02 
 
0.4 ± 0.04 
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Figure 5: Blood vessel diameters in MDA-MB-231 human mammary tumors in 
controls and hyperbaric oxygen (HBO) treated tumors after 11 days of treatment. A. 
Early treatment was initiated 7 days post cell injection (n=5) B. Late treatment was 
initiated 24 days post cell injection (n=4-5).  
 
A
. 
B. 
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6.5 Proliferation 
The proportion of a tumor’s cells that are in an active stage of the cell cycle could 
possibly contribute to or indicate the degree of malignancy of the tumor. For this 
reason, immunostaining was performed for proliferating cells using the Ki67 staining 
method as described under section 5.9.2.  
In the early treated group, the average proportion of proliferating in relation to total 
number of cells, were approximately 0.30. (Table 2)The corresponding value for the 
late treatment group was between 0.35 and 0.40. However, there was no statistically 
significant measurable difference between the HBO treated and the control tumors for 
neither the early nor the late treatment group.  
Based on this, the tumor growth inhibition observed in the early HBO treated tumors 
is probably not attributed to reduced density of proliferating cells. HBO does not 
appear to affect proliferation in this study. 
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7. Discussion 
The methods and results will be discussed in this section before ending up in a 
conclusion: 
7.1 Methodological aspects  
7.1.1 The cell line  
MDA-MB-231 was used because it is a well-established cell line used for both in 
vitro and in vivo studies.  The intent of using a human cell line was to make the study 
more clinically relevant, and being an addition to the two other mammary tumor 
models (one murine and one chemically induced) already studied using hyperbaric 
oxygen (109-112, 115, 116) at our laboratory. 
7.1.2 NOD/SCID mice  
Mice are suitable model animals because they breed well in a lab environment, they 
do not require large housing facilities and are easy to handle. The cons are that their 
fur and urine contains allergens, putting people working in the lab at risk of allergies. 
Weighing ethical considerations against body similarities, mice make one of the best 
compromises for human studies. Immunodeficient mice were used because they are 
less likely to reject foreign tissues in their bodies, an advantage when human cells are 
injected, as performed in our study. They are disease-free and genetically very 
similar, which makes our experiments more accurate with fewer variables to take into 
consideration. In this study, the cells were injected in animal models. In vivo method 
is preferred over in vitro studies because the conditions required to investigate are 
mostly unattainable in vitro. This is due to the tumor complexity, since the 
surrounding tissues (stroma) will infiltrate the tumor and is shown to strongly 
influence tumor growth. As a measure to prevent using more model animals than 
necessary, complying with the guidelines from the local ethical committee, each 
mouse was injected with two tumors. Female mice were used because they serve as 
an ideal hormonal microenvironment, since mamma tumors will increase much faster 
in size when implanted in female mice.  
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7.1.3 The anesthesia 
Isofluran was used because the animals were supposed to wake up quickly after 
procedures. N2O gas ensures a faster isofluran uptake. Although these substances can 
be harmful in high doses or during long term exposure, little to no side effects are 
expected when administered as in this study. Thus, this was considered the best 
method of anaesthesia for the present study.  
7.1.4 Culturing of cells  
F12K medium was used because it ensures the best growth conditions for this cell 
line and was originally developed primarily for human primary cells. Sterile 
conditions are to prevent contamination, so as to make sure the cells injected are all 
MDA-MB-231. With each cell split, the cell line is marked as a higher passage. The 
lower passages, that we used, are preferred because the likelihood of unknown 
mutations is less. The cell line has nevertheless regularly been tested to confirm that it 
still is MDA-MB-231.   
7.1.5 Establishing of tumors  
Cell injections were chosen over direct tumor implantation because previous studies 
have shown that if pieces of a tumor of foreign origin is to be implanted in a model 
animal in order to get tumor formation, success rates are very low (118). The take rate 
is, however, higher for cell injections. The 100% take rate indicates that the MDA-
MB-231 cell line is a suitable human cell line for tumor experiments in the 
NOD/SCID mice. Although advantages of implanting bits of tumor, is that you would 
get part of human tumor stroma, making it more like a human cancer case. The mice 
were under 3 months old when used in these experiments to avoid them regaining 
their immune system. 
 
7.1.6 HBO-treatment  
The oxygen chamber can catch fire because of the pure oxygen interior. This is 
avoided by keeping it litter and oil free. The ambient pressure needed to be a 
compromise between effect on tumor inhibition and avoiding toxicity, and a 2.5 bar 
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ambient pressure fits these criteria. This evaluation is based on previous studies from 
our laboratory. A prolonged exposure of higher oxygen partial pressure might have 
resulted in oxygen toxicity, inducing seizures, short-sightedness, inner ear trauma or 
lung problems. The experimental setup, including number of days from cell injection 
to sacrifice, and exposure time to HBO and time in between was the same as previous 
studies from our group so as to compare. The late treatment started where the longest 
previous studies had cut off (17 days) to evaluate what would happen if treatment 
started at this later stage. We had a conservative decompress and compress rate to 
avoid volume expansion or compression of the gas-filled cavities in the bodies of the 
mice, according to Boyle’s law.  
7.1.7 Chemotherapy  
The drug 5-Fluoruracil was used because it is a commonly used chemotherapeutic 
drug that is readily available. We injected between the tumors to ensure that the drug 
would be able to affect both of them. The chosen dosage is a compromise between 
effect and toxity and is perhaps a bit lower than anticipated since HBO reduced tumor 
sizes more than 5FU alone. 
7.1.8 Tumor growth 
The tumors were measured externally with a calliper. This was considered the best 
way to do it since the mice needed to be alive for the rest of the test period. 
Measurements were performed in two dimensions. The formula assumed a cylindrical 
shape and this is not exactly correct but the best option under the circumstances. 
Since the same person measured all tumors, the inaccuracies would be minimal 
between controls and HBO tumors. 
7.1.9 Immunohistochemistry and quantification techniques  
CD31 is commonly used for staining blood vessels, and our primary and secondary 
antibodies are well established. CD31 could possibly also stain lymph tissues, since it 
contains the same target molecules, thus creating faulty results. However, for a tumor 
it is suitable, since tumors generally do not contain lymph tissue. 
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The quantification of blood vessels involved manually counting blood vessels. This 
method is vulnerable to human error, but the same person did all measurements, so 
inaccuracies will ideally be equally big between groups. This was nevertheless 
considered a good method, because a person can better use their judgement to 
distinguish what is a vessel than a computer software due to the non-uniform tumor 
blood vessels. The entire cross-section area was quantified, making data more 
reliable. 
However, the diameters were measured by a computer to increase accuracy. Five 
representable areas (x100 magnification) for each tumor was chosen. This is a reliable 
estimate for the blood vessel diameters for the tumor as a whole.  
The KI67 method is also a common immunostaining procedure. The stained cells 
were counted manually in addition to non-proliferating cells. This tedious method is 
more accurate than a computer measuring areas specifically colored vs uncoloured 
areas of the tumor. A possible source of error is poor staining, which makes 
distinguishing proliferating cells from non-proliferating cells difficult. Four 
representative areas (x100 magnification) from the tumor cross-sections were 
quantified as an estimate for the entire tumor. We alternated between HBO and 
control slides when counting to even out subjective bias.  
A possible source of error concerning immunohistochemistry, is that in some cases 
two tumors deriving from the same individual, were used, while other mice were just 
represented by a single tumor. Since different genetic processes occurred in the 
different mice, despite their over all very similar gentic profile, this could be a 
problem. The variation would be much less between two from the same mouse 
compared to two from different mice, affecting the statistical significance of the data. 
7.2 Evaluation of results 
7.2.1 Body weight 
Weight changes can be a good indicator of health and disease in the model animals. A 
significant weight loss could be unethical. However, the body weight remained stable 
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throughout the experiment, indicating no influence of HBO, chemotherapy or cancer 
progression.  
7.2.2 Tumor growth  
These tumors did not grow in an exponential manner, possibly because the cells were 
obtained from a different species.  
Tumors responded in general relatively heterogenic to the same treatment. This 
strengthens the hypothesis that the genome of cancer cells is unstable and prone to 
mutations.  
Early treatment: The present study showed a significant MDA-MB-231 mammary 
tumor growth inhibition after early HBO treatment. The hyperoxia has thus executed 
some type of anti-cancer function. This corresponds to what is previously found in 
our lab in both chemically (110-112, 116) and murine (109, 111, 115) mammary 
tumors. Kluft et al. showed an inhibition of transplanted mammary carcinomas in C57 
black mice after HBO treatment (114). Granowitz et al. demonstrated strong anti-
proliferative effect of HBO on different mamma cancer cells in vitro (117). Thus, 
HBO seem to have an inhibitory effect on mammary tumors in general. 
Since angiogenesis is important for tumor growth, differences in tumor blood vessel 
density is one possible cause for the differences in size between the controls and HBO 
measured in the MDA-MB-231 tumors. However, blood vessel density and size was 
unchanged. Thus, hyperoxia did not affect blood vessels in these MDA-MB-231 
mammary tumors. This is in contrast to what was found in intermittently HBO 
exposed DMBA and 4TI tumors, and might be due to the difference in tumor type.  
The anti-tumor effect found after HBO could also be due to reduced proliferation of 
tumor cells. However, the anti-tumor effects were not caused by a change of density 
of proliferating cells as shown in our study. This is in contrast to the anti-proliferation 
effect of HBO found in DMBA tumors  in vivo and in different mammary tumor cells 
in vitro (117). 
However, the inhibitory effects of HBO on the tumors might be due to enhanced 
density of apoptotic cells and/or different levels of ROS.  
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ROS: Reactive oxygen species, or free radicals, occurs in all eukaryotic cells during 
aerobic metabolism. Normal tissues experiences lower levels of ROS that are 
furthermore properly controlled by antioxidants (121, 122). ROS can be induced by 
hypoxia, reoxygenation (reperfusion) or hyperoxia (as in our experiment). Cancer 
tissue, in contrast to non-cancerous tissues, fluctuates between periods of hypoxia and 
reperfusion due to poor vasculature. This is a major cause of oxidative stress in 
tumors, which increases ROS production (123). ROS can be harmful for lipids, 
proteins, carbohydrates and nucleic acids (124). Heightened levels of ROS, causes 
breaks of the DNA. The mutations that ensue may promote oncogenic transformation 
and apoptosis malfunction (125, 126). Studies strongly indicate a connection between 
ROS and carcinogenesis (121, 127, 128). 
When ROS levels are lower, by tumor standards, initially in cancer development, it 
has tumorigenic properties. However, when reaching sufficiently high levels, ROS 
has a toxic effect on tumors, as demonstrated in various experiments (122, 129). The 
HBO might ensure that ROS reaches this limit and cancer cells are destroyed, which 
several studies can attest to (130, 131).  
The added oxidative stress of ROS induces apoptosis at first. Interestingly though, as 
cancer progresses to a highly malignant stage, apoptosis is down-regulated and 
antioxidants activated, and the cancer cells can form a colony (121). However, if 
treatment is continued long enough, the antioxidant system will weaken and lose its 
ability to counteract ROS. This is called the “threshold effect” Apoptosis and 
permanent damage is inflicted upon cancer cells as a result (122, 132-134). This 
might be how HBO inhibits tumor growth, in the cancer cases were HBO has this 
effect. Nevertheless, if ROS was enhanced after HBO, we would expect a similar 
inhibitory effect after late HBO treatment. Furthermore, ROS was unchanges in the 
DMBA study (111) after HBO treatment, indicating this to less likely be the reason 
for tumor growth inhibition in our study. 
 
Another explanatory mechanism is the Hypoxia inducible factor-1 (HIF-1). It 
regulates cellular processes and is strongly influenced by oxygen (135). If HIF-1 is 
exposed to a normoxic environment, the HIF-1α subunit is degraded. In contrast, 
hypoxia will stabilize HIF-1α. A functional HIF-1α causes transcription of genes for 
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proteins promoting O2 delivery (VEGF-vascular endothelial growth factor, 
erythropoietin). A downregulation of HIF during HBO would nevertheless also 
induce an anti-angiogenic effect we could not demonstrate However, it improves the 
metabolism in oxygen-poor surroundings by various adaptations. (136) making them 
less aggressive.  
 
Late treatment: In the late treatment group there was a trend towards reduced tumor 
growth after HBO treatment. However, it was not significant because of the big 
deviation in responses. Thus, giving HBO at a late stage does not have an effect on 
this human mammary tumor model, indicating that elevated oxygen influences the 
internal genetics and or metabolic factors involved in the early development of these 
tumors. It seems that to treat this type of tumor, an early treatment is necessary to 
obtain desirable results.  
HBO and chemotherapy:  
HBO has previously been shown to enhance the chemotherapeutic effect in different 
solid tumors (111). However, the combined HBO/5FU therapy caused approximately 
the same degree of tumor inhibition as HBO alone. This might tells us that HBO did 
not potentiate the uptake or enhance the effect of chemotherapy in the present human 
MDA-321 tumor model, that our metod of giving the drug ip between the two tumors 
was inefficient, or that the drug amount was not enough. The interstitial fluid pressure 
might have been too high for the drug to reach the tumor cells. 
There were several reasons we expected HBO to enhance the chemotherapeutic effect 
as a tumor inhibitor. In previous studies by our group, they’ve demonstrated HBO as 
an adjuvant to chemotherapy (111, 113). Underlying reasons are further discussed. 
Hypoxic cells enter a static phase of the cell cycle. This presents a dilemma for 
radiotherapy and chemotherapy that selectively targets cells undergoing high levels of 
mitosis, as shown in experiments(137). Hypoxic tumors are generally denser in tissue 
composition than their surroundings, and the tumors present interstitial hypertension 
(138).  
An attempt to understand the underlying mechanisms for the tumor inhibitory effect 
of HBO, my speculations: It is possible that an oxygen deprived tumor that is exposed 
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to a rich supply of oxygen, will perceive this as a sign that it did not just get more 
oxygen, but also more nutrients and removal of waste products and carbon monoxide. 
This seems legit, because in nature, more oxygen is always associated with blood 
vessels. In this artificial setting, it only gets the oxygen and nothing else. So the tumor 
“thinks” it has all these other benefits and turn off genetic mechanisms that it 
“believes” to be unnecessary. The result: tumor inhibiton. 
7.3 Conclusion 
Aim 1: To develop a human breast tumor (MDA-MB-231) in NOD/SCID mice after 
injecting human breast cancer cells into the groin area  
We successfully developed a human breast cancer model in NOD/SCID mice. 
Aim 2: To investigate if HBO (early or late treatment) have an effect on angiogenesis, 
proliferation and growth in the present mammary tumor model  
Hyperoxia had a strong inhibitory effect on MDA-231 mammary tumors if HBO 
was administered early, but not if HBO  was given late. Hyperoxia did not 
influence angiogenesis or proliferation in the present model.  
Aim 3: To investigate if HBO potentiate the tumor inhibitory effect of chemotherapy 
in the same mammary tumor model 
HBO did not potentiate the effect of chemotherapy on the present mammary 
model. 
7.4 Further studies 
In the future, studies aimed at elucidating the genetic mechanisms underlying the 
tumor inhibitory effect of HBO, by use of proteomic and genetic analysis could be of 
value, in order to investigating exactly how this effect occurs and what particular 
mechanisms are involved.  
Detailed studies of tumor pathology after HBO exposure could reveal morphological 
changes.  
  
35 
35 
It would also be of interest to combine HBO with other treatments to measure the 
combined effect, in addition to understand the results obtained at a genetic level. 
Since different tumor types respond radically different to the same treatment (HBO), 
it would be interesting to pin point the exact qualities of each tumor type that make 
them either responders or non-responders. 
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